NetScientific (GB:EMVC) has released an update.
EMV Capital’s portfolio company, PDS Biotechnology, has updated its clinical programs and financial results for the third quarter of 2024, showing a net loss of $10.7 million. The company is advancing its VERSATILE-003 Phase 3 trial for HPV16-positive head and neck cancer, with FDA clearance expected by mid-December. PDS Biotech is also exploring further development of its Versamune® HPV immunotherapy following promising results in treating cervical cancer.
For further insights into GB:EMVC stock, check out TipRanks’ Stock Analysis page.
